Hutchins Lisa M, Temple Joel D, Hilmas Elora
Bloomberg Children's Center (LMH), Johns Hopkins Hospital, Baltimore, Maryland, Nemours/Alfred I. duPont Hospital for Children (JDT, EH), Wilmington, Delaware.
J Pediatr Pharmacol Ther. 2017 Nov-Dec;22(6):399-405. doi: 10.5863/1551-6776-22.6.399.
To determine whether dedicated pharmacy services improve the rate of electrocardiogram (ECG) monitoring in patients at risk for medication-induced QTc interval prolongation. In addition, determine how pediatric institutions currently monitor patients at risk for medication-induced QTc interval prolongation.
A pharmacist-driven monitoring protocol to detect medication-induced QTc interval prolongation was developed using published literature. If patients were prescribed 3 or more medications known to prolong the QTc interval, they were recommended to have a baseline ECG to assess the QTc interval. If 3 or more QTc interval-prolonging medications were administered for 5 or more days, a follow-up ECG was recommended. Patients prescribed medications known to prolong the QTc interval were identified. Prior to pharmacist intervention, electronic medical records were reviewed to determine if baseline and follow-up ECGs were obtained in patients meeting criteria for monitoring. A dedicated pharmacist then prospectively reviewed charts and recommended monitoring. The rate of monitoring during the intervention and baseline period was compared. To determine current practice at pediatric institutions, a survey was distributed to pharmacists.
Pharmacist intervention improved the rate of ECG monitoring in patients at risk for medication-induced QTc interval prolongation from 47.8% to 100% (p = 0.0009). Of the 55 survey participants, 6 stated their institution had QTc interval monitoring procedures in place, 35 did not have any, and 3 had procedures in process.
Targeted pharmacist intervention improved the rate of ECG monitoring in patients at risk for medication-induced prolonged QTc interval. Our research and survey data reveal that institutions could benefit from targeted pharmacist intervention to monitor patients for medication-induced QTc interval prolongation.
确定专门的药学服务是否能提高药物性QTc间期延长风险患者的心电图(ECG)监测率。此外,确定儿科机构目前如何监测药物性QTc间期延长风险患者。
利用已发表的文献制定了由药剂师驱动的监测方案,以检测药物性QTc间期延长。如果患者被开具3种或更多已知可延长QTc间期的药物,则建议其进行基线心电图检查以评估QTc间期。如果使用3种或更多可延长QTc间期的药物达5天或更长时间,则建议进行随访心电图检查。识别出被开具已知可延长QTc间期药物的患者。在药剂师干预之前,查阅电子病历以确定符合监测标准的患者是否进行了基线和随访心电图检查。然后由一名专门的药剂师前瞻性地查阅病历并建议进行监测。比较干预期和基线期的监测率。为了确定儿科机构的当前做法,向药剂师发放了一份调查问卷。
药剂师干预使药物性QTc间期延长风险患者的心电图监测率从47.8%提高到了100%(p = 0.0009)。在55名参与调查者中,6人表示其所在机构有QTc间期监测程序,35人表示没有任何程序,3人表示程序正在制定中。
有针对性的药剂师干预提高了药物性QTc间期延长风险患者的心电图监测率。我们的研究和调查数据表明,机构可从有针对性的药剂师干预中受益,以监测患者是否出现药物性QTc间期延长。